Stempoint Capital’s BridgeBio Pharma BBIO Stock Holding History

Stempoint Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-127,435	Closed	-$6.62M	–	86
2025 Q3	$6.62M	Buy	127,435 +72,805	+133%	+$3.55M	1.33%	24
2025 Q2	$2.36M	Sell	54,630 -153,807	-74%	-$5.59M	0.76%	37
2025 Q1	$7.21M	Buy	+208,437	New	+$7.03M	2.3%	15
2024 Q4	–	Sell	-94,885	Closed	-$2.42M	–	60
2024 Q3	$2.42M	Buy	+94,885	New	+$2.49M	0.72%	34
2024 Q1	–	Sell	-253,948	Closed	-$10.3M	–	70
2023 Q4	$10.3M	Buy	+253,948	New	+$7.63M	2.74%	9

Other funds holding BBIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stempoint Capital's BBIO Position: Q4 2025 in Review

Stempoint Capital sold out of BridgeBio Pharma (BBIO) in Q4 2025, closing a stake of 127,435 shares — an estimated $6.62M sold.

Stempoint Capital first reported a position in BBIO in Q4 2023 and held it in 5 quarters. The position peaked at $10.3M in Q4 2023. 433 funds tracked by Wall St. Rank hold BBIO as of Q4 2025.

Stempoint Capital reported no remaining BridgeBio Pharma position as of Q4 2025 after selling out during the quarter.
Stempoint Capital sold 127,435 BridgeBio Pharma shares in Q4 2025, an estimated $6.62M.
Stempoint Capital first reported a position in BridgeBio Pharma in Q4 2023 and held it in 5 quarters.
Stempoint Capital's BridgeBio Pharma position peaked at $10.3M in Q4 2023.
433 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.